Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
12 p, 710.3 KB Pazopanib : Evidence review and clinical practice in the management of advanced renal cell carcinoma / Méndez-Vidal, María José (Hospital Reina Sofía, Córdoba) ; Molina, Áurea (Complejo Hospitalario Universitario A Coruña) ; Anido, Urbano (Complejo Hospitalario Universitario de Santiago) ; Chirivella, Isabel (Hospital Clínico Universitario de Valencia) ; Etxaniz, Olatz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fernández-Parra, Eva (Hospital Nuestra Señora del Valme) ; Guix, Marta (Hospital del Mar) ; Hernández, Carolina (Hospital Universitario Nuestra Señora de Candelaria) ; Lambea, Julio (Hospital Clínico Universitario Lozano Blesa) ; Montesa, Álvaro (Hospital Regional de Málaga) ; Pinto, Álvaro (Hospital la Paz) ; Ros, Silverio (Hospital Universitario Virgen de la Arrixaca) ; Gallardo, Enrique (Parc Taulí Hospital Universitari) ; Universitat Autònoma de Barcelona
Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. [...]
2018 - 10.1186/s40360-018-0264-8
BMC Pharmacology & Toxicology, Vol. 19 (november 2018)  
2.
9 p, 341.6 KB Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ; Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ; Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ; Romanel, A. (Università di Trento. Centro di Biologia Integrata) ; Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ; González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ; Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ; Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ; Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ; Climent, M. A. (Instituto Valenciano de Oncología) ; Duran, I. (Instituto de Biomedicina de Sevilla) ; Gallardo, E. (Hospital Universitari Parc Taulí. Departament d'Oncologia Médica) ; Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ; Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ; Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ; Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ; Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ; Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ; De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Spanish Oncology Genitourinary Group ; Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of Oncology, Núm. 28 (2017) , p. 1508-1516  
3.
12 p, 5.3 MB Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma / Puente, Javier (Hospital Clínico Universitario San Carlos) ; Laínez, Nuria (Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain) ; Dueñas, Marta (CIBERONC, Spain) ; Méndez-Vidal, María José (Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain) ; Esteban, Emilio (Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain) ; Castellano, Daniel (Medical Oncology Department, and Instituto Investigación Biomédica, Hospital Universitario 12 de Octubre, Madrid, Spain) ; Martinez-Fernández, Mónica (CIBERONC, Spain) ; Basterretxea, Laura (Medical Oncology Department, Hospital Donostia, Donostia, Spain) ; Juan-Fita, María José (Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain) ; Antón, Luis (Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain) ; León, Luis (Promoción e Planificación da Investigación Sanitaria, Axencia de Coñecemento en Saúde, Santiago de Compostela, Spain) ; Lambea, Julio (Medical Oncology Department, Hospital Clínico de Zaragoza, Zaragoza, Spain) ; Pérez-Valderrama, Begoña (Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain) ; Vázquez, Sergio (Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain) ; Suarez, Cristina (Universitat Autònoma de Barcelona) ; del Muro, Xavier Garcia (Institut Català d'Oncologia, Hospital Duran i Reynals) ; Gallardo, Enrique (Medical Oncology Department, Hospital Universitari Parc Taulí, Sabadell, Spain) ; Maroto, José Pablo (Institut d'Investigacions Biomèdiques Sant Pau) ; Samaniego, M Luz (Statistical Department, Trial Form Support TFS people, Madrid, Spain) ; Suárez-Paniagua, Beatriz (Oncology Medical Department, Trial Form Support, Madrid, Spain) ; Sanz, Julián (Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain) ; Paramio, Jesús M. (CIBERONC, Spain)
Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. [...]
2017 - 10.18632/oncotarget.16494
Oncotarget, Vol. 8 (march 2017) , p. 30410-30421  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.